Overview of Specific Molecular Targeted Agents for Combined Modality Therapy

作者: Scott Saxman , Janet Dancey

DOI: 10.1007/978-1-59259-325-5_17

关键词:

摘要: Despite recent advances in the technology and techniques for delivering radiotherapy to patients with malignancies, inability of maximally tolerated doses radiation locally eradicate all malignant cells remains a major clinical problem leading failure overall treatment plan. As described by Rosen et al., there are variety reasons why tumors recur after (1–3). A “geographic miss” occurs when portion observable tumor volume is excluded from port those receive nominal dose radiation. Frequently, distribution gross uneven, central targeted receiving higher quantity than at peripheral tumor/normal tissue interface. These edge therefore can subtherapeutic or sublethal retain ability regrow repopulate. This referred as “marginal miss.” Irradiated tissues also potentially be recolonized regional anatomic sites hematogenous dissemination. “repopulation.” However, cause local recurrence tolerable dosages completely eliminate within mass. Radioresistance this sense relative, since presumably that would kill if toxicity factors inherent host did not preclude its delivery.

参考文章(98)
Y Ohsaki, S Tanno, Y Fujita, E Toyoshima, S Fujiuchi, Y Nishigaki, S Ishida, A Nagase, N Miyokawa, S Hirata, K Kikuchi, Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncology Reports. ,vol. 7, pp. 603- 610 ,(2000) , 10.3892/OR.7.3.603
Eliot M. Rosen, Saijun Fan, Sara Rockwell, Itzhak D. Goldberg, The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Investigation. ,vol. 17, pp. 56- 72 ,(1999) , 10.1080/07357909909011718
Kathleen F. Pirollo, Zhengmei Hao, Antonina Rait, Chong Wai Ho, Esther H. Chang, Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochemical and Biophysical Research Communications. ,vol. 230, pp. 196- 201 ,(1997) , 10.1006/BBRC.1996.5922
Marie Prewett, Howard I. Scher, Patricia Rockwell, R F Rockwell, Nicholas A. Giorgio, John Mendelsohn, Neil I. Goldstein, The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma Journal of Immunotherapy. ,vol. 19, pp. 419- 427 ,(1996) , 10.1097/00002371-199611000-00006
Peter Traxler, Pascal Furet, Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors Pharmacology & Therapeutics. ,vol. 82, pp. 195- 206 ,(1999) , 10.1016/S0163-7258(98)00044-8
Wayne D. Klohs, David W. Fry, Alan J. Kraker, Inhibitors of tyrosine kinase. Current Opinion in Oncology. ,vol. 9, pp. 562- 568 ,(1997) , 10.1097/00001622-199711000-00012
Boguslaw Maciejewski, H.Rodney Withers, Jeremy M.G. Taylor, Andrzej Hliniak, Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. International Journal of Radiation Oncology Biology Physics. ,vol. 16, pp. 831- 843 ,(1989) , 10.1016/0360-3016(89)90503-8
J.R Woodburn, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics. ,vol. 82, pp. 241- 250 ,(1999) , 10.1016/S0163-7258(98)00045-X
Emiko Tsuchida, Muneyasu Urano, The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma International Journal of Radiation Oncology Biology Physics. ,vol. 39, pp. 1153- 1161 ,(1997) , 10.1016/S0360-3016(97)00549-X
W.Gillies McKenna, Marisa C. Weiss, Vincent J. Bakanauskas, Howard Sandler, Martin L. Kelsten, John Biaglow, Stephen W. Tuttle, Brian Endlich, C.Clifton Ling, Ruth J. Muschel, The role of the H-ras oncogene in radiation resistance and metastasis International Journal of Radiation Oncology*Biology*Physics. ,vol. 18, pp. 849- 859 ,(1990) , 10.1016/0360-3016(90)90407-B